Synthetic Approaches to Physiologically Active Polycyclic Compounds: VII.* Synthesis of 2-(7-Hydroxybicyclo-[3.3.1]non-3-ylmethyl)propane-1,3-diol

O. N. Zefirova^a, E. V. Nurieva^a, V. N. Nurieva^a, A. A. Ivanov^b, N. V. Zyk^a, and N. S. Zefirov^{a, b}

^a Faculty of Chemistry, Moscow State University, Vorob'evy gory 1, Moscow, 119992 Russia ^b Institute of Physiologically Active Substances, Russian Academy of Sciences, Chernogolovka, Moscow oblast, Russia

Received January 5, 2008

Abstract—2-(*endo*-7-Hydroxybicyclo[3.3.1]non-*exo*-3-ylmethyl)propane-1,3-diol was synthesized in seven steps starting from *endo*-7-hydroxybicyclo[3.3.1]nonane-*exo*-3-carboxylic acid. The title compound attracts interest as intermediate product for the synthesis of potential tubulin ligands.

DOI: 10.1134/S1070428008080058

In the framework of our studies on the synthesis of simple analogs of the known antitumor agent taxol [1-6] we are developing methods for the preparation of substituted adamantanes and bicyclo[3.3.1]nonanes containing an amino acid fragment [(2R,3S)-N-ben-zoylphenylisoserine] and an oxetane ring connected to the cage-like fragment through a short linker [7].



Simulation of docking of such structures into the taxol binding site on β -tubulin** showed that the length of the linker should be equal to the length of one methylene group to ensure the same orientation of the amino acid residue as in the taxol molecule (structure I).



* For communications I–VI, see [1–6].

Provided that the substituent on C^7 has *exo* orientation, the oxygen atom in the oxetane ring of molecule I can be involved in hydrogen bonding with the amino group in the main Thr276 chain of tubulin, in a way similar to the natural molecule (Fig. 1).



We planned to synthesize compound I via esterification of the corresponding cage-like alcohol II with amino acid [8]. In the initial stage of the development



Fig. 1. Docking of compound I into the taxol binding site on β -tubulin.

^{**} The model was kindly provided by Prof. J. Snyder (USA). Molecular modeling studies were performed in collaboration with the Prof. K.A. Jacobson Laboratory (National Institute of Diabetes & Digestive & Kidney Diseases, NIH, USA).



of synthetic procedure we tried to obtain an intermediate compound capable of forming oxetane fragment, namely 2-(*endo*-7-hydroxybicyclo[3.3.1]non-*exo*-3-ylmethyl)propane-1,3-diol (**XI**). It should be noted that ring closure of 1,3-diols is one of the main methods for building up oxetane ring (oxetan-3-ol and the corresponding taxol fragment are obtained just in this way) [7, 9, 10].

As starting compound for the synthesis of diol XI we used *endo*-7-hydroxybicyclo[3.3.1]nonane-*exo*-3carboxylic acid (III) which was prepared by alkaline hydrolysis of 2-oxahomoadamantan-3-one. Acid III is a template with the required configuration of substituents (*endo*, *exo*) [11, 12]; following standard procedures including protection of the hydroxy group and reduction of the carboxy group, we obtained alcohol VI (Scheme 1). We tried to effect further modification of alcohol VI in two ways. However, our attempt to convert it into the corresponding iodide (with a view to react the latter with dimethyl malonate sodium salt) was unsuccessful: only the initial compound was isolated in the reaction of methanesulfonate VII with potassium iodide in acetone [9]. On the other hand, we succeeded in oxidizing compound VI to aldehyde VIII for subsequent condensation with dimethyl malonate. The oxidation of VI with pyridinium dichromate gave aldehyde VIII in 69% yield. Swern oxidation of compound VI was characterized by very poor yield, so that aldehyde VIII could not be isolated as individual substance.

The condensation of aldehyde **VIII** with dimethyl malonate afforded compound **IX** which was reduced with hydrogen in methanol over palladium catalyst. The reduction was accompanied by removal of the tet-

rahydropyranyl protection with formation of hydroxy ester **X**. The subsequent reduction of **X** with lithium tetrahydridoaluminate gave the target triol **XI**. The structure of the isolated compounds (compounds V-XIwere previously unknown) was proved by elemental analysis and ¹H and ¹³C NMR spectroscopy. Studies on the synthesis of compounds **II** and **I** from triol **XI** are now in progress.

EXPERIMENTAL

The ¹H and ¹³C NMR spectra were recorded on a Varian VXR-400 spectrometer at 400 and 100 MHz, respectively, using hexamethyldisiloxane (for **IV**) or tetramethylsilane as internal reference. The progress of reactions was monitored by TLC on Silufol UV-254 plates. Column chromatography was performed on silica gel (Acros, 40–60 µm).

Methyl *endo*-7-hydroxybicyclo[3.3.1]nonane*exo*-3-carboxylate (IV) was synthesized according to standard procedure from 2 g (11 mmol) of acid III and 2 ml of boron trifluoride–diethyl ether complex in 20 ml of methanol. The product was purified by chromatography using ethyl acetate–petroleum ether (bp 40–60°C) (3:1) as eluent. Yield 1.9 g (90%), colorless crystals (in the cold), mp 50–51°C. ¹H NMR spectrum (CDCl₃), δ , ppm: 1.21–1.44 m (3H), 1.66–1.79 m (3H), 2.02–1.90 m (3H), 2.26–2.43 m (4H), 3.20 m (1H, 3-H), 3.52 s (3H, CH₃O), 3.84 m (7-H). ¹³C NMR spectrum (CDCl₃), δ_C , ppm: 26.01 (CH₂), 29.70, 30.01, 34.61 (CH₂), 36.18, 51.42 (OCH₃), 63.77 (CHOH), 177.68 (C=O).

Methyl endo-7-(tetrahydro-2H-pyran-2-yloxy)bicvclo[3.3.1]nonane-exo-3-carboxylate (V) was synthesized according to standard procedure from 0.66 g (3.3 mmol) of hydroxy ester IV and 0.48 ml (5.5 mmol) of 3,4-dihydro-2H-pyrane in 20 ml of methylene chloride in the presence of 0.07 g of triphenylphosphine hydrobromide. Yield 0.92 g (98%). Yellowish oily substance. ¹H NMR spectrum (CDCl₃), δ, ppm: 1.28–1.31 m (1H), 1.42–1.45 m (1H), 1.56– 1.62 m (8H), 1.71-1.84 m (4H), 2.06-2.19 m (4H), 3.42-3.52 m (2H, 7-H, 3-H), 3.67 s (3H, CH₃), 3.88-3.95 m (2H, CH₂O), 4.70–4.72 m (1H, OCHO). ¹³C NMR spectrum (CDCl₃), $\delta_{\rm C}$, ppm (a mixture of two stereoisomers at $C^{2'}$): 19.73, 26.16, 26.24, 30.55, 31.27, 33.18, 34.08, 34.53, 34.57, 35.02 (C³), 51.43 (CH₃), 62.52 (CH₂O), 68.71 (C⁷), 96.97 (OCHO), 177.85 (C=O). Found, %: C 68.11; H 9.18. C₁₆H₂₆O₄. Calculated, %: C 68.06; H 9.28.

endo-7-(Tetrahydro-2H-pyran-2-yloxy)bicyclo-[3.3.1]non-exo-3-ylmethanol (VI).*** Compound V, 0.50 g (1.8 mmol), was added to a suspension of 0.12 g(3 mmol) of LiAlH₄ in 20 ml of diethyl ether, the mixture was heated for 3 h under reflux, and 0.2 ml of water was added dropwise. The product was purified by flash chromatography using ethyl acetatepetroleum ether (bp 40-60°C) (1:3) as eluent. Yield 0.44 g (97%), colorless crystals, mp 86–87°C. ¹H NMR spectrum (CDCl₃), δ, ppm: 1.10–1.38 m (5H), 1.55– 1.86 m (10H), 2.16–2.35 m (5H), 3.46–3.52 m (3H, CH₂OH, 3-H), 3.89–3.94 m (2H, CH₂O), 4.69 m (1H, OCHO). ¹³C NMR spectrum (CDCl₃), δ_{C} , ppm (a mixture of two stereoisomers at $C^{2'}$): 19.82, 26.19, 26.28, 29.88, 30.41, 31.29, 32.83, 34.62, 36.02, 36.12, 62.41 (CH₂O), 69.27 (CH₂OH), 69.32 (C⁷), 96.14, 96.84 (OCHO). Found, %: C 70.50; H 10.26. C₁₅H₂₆O₃. Calculated, %: C 70.83; H 10.30.

endo-7-(Tetrahydro-2H-pyran-2-yloxy)bicyclo-[3.3.1]non-exo-3-ylmethyl methanesulfonate (VII) was synthesized according to standard procedure from 0.46 g (1.8 mmol) of alcohol VI in 20 ml of methylene chloride and 0.15 ml (2 mmol) of methanesulfonyl chloride in the presence of 0.2 ml of pyridine. The product was purified by flash chromatography using ethyl acetate-petroleum ether (bp 40-60°C) (1:3) as eluent. Yield 0.51 g (85%), oily liquid. ¹H NMR spectrum (CDCl₃), δ, ppm: 1.19–1.85 m (14H), 2.09– 2.29 m (4H), 2.76-2.83 m (1H, 3-H, J = 12.72, 6.06 Hz), 3.01 s (3H, CH₃), 3.49–3.53 m (1H, 7-H), 3.87-3.94 m (2H, CH₂OCH), 4.05 d (2H, CH₂OMs, J = 6.06 Hz), 4.68 m (1H, OCHO). ¹³C NMR spectrum (CDCl₃), δ_{C} , ppm (a mixture of two stereoisomers at C^{2'}): 19.90, 26.05, 26.15, 27.95, 30.51, 31.28, 33.13, 34.94, 35.08, 35.17, 37.21 (CH₃); 62.70 (CH₂O), 68.87 (C⁷), 75.89 (CH₂OMs), 97.10 (OCHO). Found, %: C 57.78; H 8.45. C₁₆H₂₈O₅S. Calculated, %: C 57.80; H 8.49.

endo-7-(Tetrahydro-2*H*-pyran-2-yloxy)bicyclo-[3.3.1]nonane-*exo*-3-carbaldehyde (VIII). Pyridinium dichromate, 1.1 g (3 mmol), was added to a solution of 0.5 g (2 mmol) of alcohol VI in 30 ml of methylene chloride. The mixture was stirred for 2 h at room temperature and filtered, the precipitate was washed with methylene chloride, and the filtrate was evaporated. The residue was purified by chromatog-

^{***} The syntheses of compounds **IV–VI** were performed with participation of student M.V. Kiryukhin (Faculty of Chemistry, Moscow State University).

(C⁷), 170.20 (C=O). Found, %: C 63.40; H 8.48. C₁₅H₂₄O₅. Calculated, %: C 63.36; H 8.51.

60°C) (1:7) as eluent. Yield 0.34 g (69%), oily liquid. ¹H NMR spectrum (CDCl₃), δ , ppm: 1.24–1.43 m (1H), 1.46–1.50 m (9H), 1.67–1.88 m (4H), 2.02– 2.20 m (4H), 3.39–3.52 m (2H, 3-H, 7-H), 3.86– 3.94 m (2H, CH₂OCH), 4.68 m (1H, OCHO), 9.63 m (1H, CHO). ¹³C NMR spectrum (CDCl₃), δ_{C} , ppm (a mixture of two stereoisomers at C²): 19.86, 25.50, 25.85, 25.97, 31.07, 31.27, 31.30, 33.45, 35.25, 41.83 (C³); 62.65 (CH₂O), 68.55 (C⁷), 97.10 (OCHO), 205.86 (CHO).

raphy using ethyl acetate-petroleum ether (bp 40-

Dimethyl 2-{endo-7-(tetrahydro-2H-pyran-2-yloxy)bicyclo[3.3.1]non-exo-3-ylmethylidene}malonate (IX). A mixture of 0.30 g (1.2 mmol) of aldehyde VIII, 0.16 mg (1.2 mmol) of dimethyl malonate, and 0.01 g of ethylenediammonium diacetate in 50 ml of benzene was heated for 8 h in a flask equipped with a Dean-Stark trap. The product was isolated by chromatography using ethyl acetate-petroleum ether (bp 40-60°C) (1:7) as eluent. Yield 0.23 g (52%), colorless crystals, mp 82-84°C. ¹H NMR spectrum (CDCl₃), δ, ppm: 1.09–1.12 m (1H), 1.19–1.37 m (4H), 1.48–1.68 m (8H), 1.76–1.81 m (1H), 2.09– 2.19 m (4H), 3.14–3.23 m (1H, 3-H), 3.42–3.46 m (1H, 7-H), 3.73 s (3H, CH₃), 3.81 s (3H, CH₃), 3.83-3.87 m (2H, CH₂O), 4.60 m (1H, OCHO), 6.82 d (1H, CH=C, J = 9.85 Hz). ¹³C NMR spectrum (CDCl₃), δ_{C} , ppm (a mixture of two stereoisomers at C^{2'}): 20.07, 25.48, 25.74, 25.85, 29.30, 29.57, 31.20, 32.53, 34.35, 37.84, 52.19 (CH₃), 52.25 (CH₃), 62.89 (CH₂O), 68.72 (C⁷), 97.15 (OCHO), 126.26 (CH=C), 155.35 (CH=C), 164.64 (C=O), 165.91 (C=O). Found, %: C 65.55; H 8.31. C₂₀H₃₀O₆. Calculated, %: C 65.55; H 8.25.

Dimethyl 2-(*endo***-7-hydroxybicyclo[3.3.1]non***exo***-3-ylmethyl)malonate (X).** A mixture of 0.12 g (0.3 mmol) of compound IX and 0.10 g of Pd/C in methanol was stirred for 12 h at room temperature in a stream of hydrogen (1 atm). The mixture was filtered, the filtrate was evaporated, and the residue was purified by flash chromatography using ethyl acetate–petroleum ether (bp 40–60°C) (1:5) as eluent. Yield 0.09 g (99%), oily liquid. ¹H NMR spectrum (CDCl₃), δ , ppm: 0.98–1.15 m (5H), 1.55–1.58 m (3H), 1.77–1.81 m (2H), 1.92–2.02 m (2H), 2.07–2.17 m (4H), 3.44–3.48 t [1H, CH(CO₂CH₃)₂, *J* = 7.71 Hz], 3.72 s (6H, OCH₃), δ_{C} , ppm: 25.42, 26.55, 29.40, 36.34, 36.40, 39.40, 49.29, 52.51 (CH₃), 64.77

2-(endo-7-hydroxybicyclo[3.3.1]non-exo-3-ylmethyl)propane-1,3-diol (XI). Compound X, 0.08 g (0.3 mmol), was added to a suspension of 0.04 g (1 mmol) of LiAlH₄ in 20 ml of diethyl ether, the mixture was heated for 3 h under reflux, and 0.1 ml of water was added. The organic phase was separated by decanting, and the residue was washed with boiling THF $(3 \times 10 \text{ ml})$. The combined organic extracts were dried over sodium sulfate and evaporated, and the residue was purified by chromatography using ethyl acetate-petroleum ether (bp 40-60°C) (1:1) as eluent. Yield 0.057 g (95%), oily liquid. ¹H NMR spectrum (CDCl₃), δ, ppm: 0.98–1.13 m (5H), 1.20–1.29 m (2H), 1.58-1.62 m (3H, J = 12.5 Hz), 1.83-1.88 m (1H, J = 10.5, 7.0, 3.4 Hz), 2.07-2.22 m (5H), 3.20-3.45 br.m (3H, OH), 3.59–3.64 d.d (2H, CH₂OH, J = 10.8, 7.2 Hz), 3.74-3.78 d.d (2H, CH₂OH, J = 10.8, 7.2 Hz), 3.91-3.99 m (1H, 7-H, J = 15.9, 8.22 Hz). ¹³C NMR spectrum (CDCl₃), $δ_{\rm C}$, ppm: 24.33, 26.76, 29.60, 35.55, 36.37, 38.92, 40.31, 64.94 (C^7), 65.63 (CH₂OH). Found, %: C 68.42; H 10.64. C₁₃H₂₄O₃. Calculated, %: C 68.38; H 10.59.

This study was performed under financial support by the Russian Foundation for Basic Research (project no. 07-03-12110-ofi), by the Chemistry and Materials Science Department of the Russian Academy of Science, and by the Program for Support of Leading Scientific Schools (project no NSh-2552.2006.3).

REFERENCES

- Zefirova, O.N., Selyunina, E.V., Averina, N.V., Zyk, N.V., and Zefirov, N.S., *Russ. J. Org. Chem.*, 2002, vol. 38, p. 1125.
- Zefirova, O.N., Selyunina, E.V., Nuriev, V.N., Zyk, N.V., and Zefirov, N.S., *Russ. J. Org. Chem.*, 2003, vol. 39, p. 831.
- Averina, N.V., Borisova, G.S., Zefirova, O.N., Selyunina, E.V., Zyk, N.V., and Zefirov, N.S., *Russ. J. Org. Chem.*, 2004, vol. 40, p. 497.
- Zefirova, O.N., Nurieva, E.V., Chekhlov, A.N., Aldoshin, S.M., Nesterenko, P.N., Zyk, N.V., and Zefirov, N.S., *Russ. J. Org. Chem.*, 2004, vol. 40, p. 502.
- Averina, N.V., Zefirova, O.N., Zefirov, N.S., Chekhlov, A.N., Shilov, G.V., and Aldoshin, S.M., *Russ. J. Org. Chem.*, 2004, vol. 40, p. 1437.
- 6. Zefirova, O.N., Nurieva, E.V., and Zyk, N.V., *Russ. J.* Org. Chem., 2005, vol. 41, p. 1286.

- Kiryukhin, M.V., Nurieva, E.V., Shishov, D.V., Zefirova, O.N., Nuriev, V.N., Zyk, N.V., and Zefirov, N.S., *Vestn. Mosk. Univ., Ser. 2: Khim.*, 2007, vol. 48, p. 342.
- Selyunina, E.V., Zefirova, O.N., Zyk, N.V., and Zefirov, N.S., *Vestn. Mosk. Univ., Ser. 2: Khim.*, 2002, vol. 43, p. 237.
- Fuji, K., Watanabe, Y., Ohtsubo, T., Nuruzzaman, M., Hamajima, Y., and Kohno, M., *Chem. Pharm. Bull.*, 1999, vol. 47, p. 1334.
- Holton, R.A., Kim, H.-B., Somoza, C., Lliang, F., Biediger, R.J., Boatman, P.D., Shindo, M., Smith, C.C., Kim, S., Nadizadeh, H., Suzuki, Y., Tao, C., Vu, P., Tang, S., Zhang, P., Murthi, K.K., Gentile, L.N., and Liu, J.H., J. Am. Chem. Soc., 1994, vol. 116, p. 1599.
- 11. Renzoni, G.E. and Borden, W.T., J. Org. Chem., 1983, vol. 48, p. 5231.
- 12. Partch, R., Brewser, W., and Stokes, B., *Croat. Chem. Acta*, 1985, vol. 58, p. 661.